Becton Dickinson Signs Sharps Agreement But Predicts Disappointing Quarter
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson's safety engineered "sharps" program with Kaiser Permanente, announced June 16, signals the initial success of a strategy that is expected to carry the company out of its recent warnings of slower growth.
You may also be interested in...
BD Expanding Safety Needle Technology Platform With Saf-T-Med Buy
Becton Dickinson plans to initiate marketing feedback studies of Saf-T-Med's Easy Safe retracting needle syringe within 12 months, the company says.
BD Expanding Safety Needle Technology Platform With Saf-T-Med Buy
Becton Dickinson plans to initiate marketing feedback studies of Saf-T-Med's Easy Safe retracting needle syringe within 12 months, the company says.
Becton Dickinson Discontinuing Glucose Monitor Development Program
Becton Dickinson's decision not to introduce a stand-alone blood glucose monitoring product by year-end gives the company extra resources to focus further on its "strategic bullseye" represented by sharps protection, biosciences and insulin delivery.